Nocturia and Its Impact on Health-related Quality of Life and Health Care Seeking Behaviour in German Community-dwelling Men Aged 50 Years or Older

Overview

Journal World J Urol

Specialty Urology

Date 2014 Aug 9

PMID 25103609

Citations 17

Authors

Matthias Oelke

Birgitt Wiese

Richard Berges

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the prevalence of nocturia/nocturnal voiding frequency and its impact on overall physical and mental health status in German community-dwelling men and determine which lower urinary tract symptom (LUTS) is responsible for medical consultations in the 2-year follow-up period.

Methods: A sample of German men aged 50-80 years from a community-dwelling study was chosen for re-evaluation 2 years after initial assessment. Men were clinically investigated and completed the International Prostate Symptom Score, American Urology Association-Symptom Problem Index (AUA-SPI), and the Short-Form Health Survey (SF-12).

Results: In total, 1,562 men were eligible for analysis. Mean nocturnal voiding frequency was 2.3 for all men and increased with ageing. SF-12 data indicated that physical but not mental health status was lower than in the average population. LUTS severity reduced both physical and mental health status (p < 0.001). Clinically relevant nocturia (≥ 2 voids/night) was present in 43 % of men and reduced both physical and mental health status (p < 0.001), whereas both HRQoL scales were not significantly reduced in men without or only one nocturnal void. In multivariate regression analysis using patient-reported bother (AUA-SPI) from LUTS, only bother from nocturnal voiding was significantly associated with medical consultations in the investigated 2-year follow-up period (odds ratio 2.6; 95 % confidence interval 1.6-4.2; p < 0.001).

Conclusions: Our study confirmed that nocturnal voiding is highly prevalent in community-dwelling men and reduce both physical and mental health status. Bother from nocturnal voiding is the most relevant component of LUTS responsible for medical consultations in German men.

Citing Articles

Modeling study of the effect of placebo and medical therapy on storage and voiding symptoms, nocturia, and quality of life in men with prostate enlargement at risk for progression.

Gravas S, Manuel-Palacios J, Chavan C, Roehrborn C, Oelke M, Averbeck M Prostate Cancer Prostatic Dis. 2023; 27(3):469-477.

PMID: 37794168 PMC: 11319195. DOI: 10.1038/s41391-023-00731-w.

[Diagnostic work-up of benign prostatic hyperplasia : The German S2e-guideline 2023 part 1].

Oelke M, Abt S, Becher K, Dreikorn K, Madersbacher S, Magistro G Urologie. 2023; 62(8):805-817.

PMID: 37401972 DOI: 10.1007/s00120-023-02142-0.

Lower urinary system symptoms and affecting factors in female students staying in a dormitory.

Ozcan H, Kizilkaya Beji N Rev Assoc Med Bras (1992). 2022; 68(7):922-927.

PMID: 35946769 PMC: 9574956. DOI: 10.1590/1806-9282.20220058.

Review: Correlation between bladder obstruction with bladder function and erectile dysfunction in mice.

Hutasoit C, Sinrang A, Hatta M, Rasyid H, Lie H Ann Med Surg (Lond). 2022; 75:103294.

PMID: 35386771 PMC: 8977939. DOI: 10.1016/j.amsu.2022.103294.

What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine.

Muderrisoglu A, Oelke M, Schneider T, Murgas S, de la Rosette J, Michel M Adv Ther. 2022; 39(6):2489-2501.

PMID: 35325367 PMC: 9123021. DOI: 10.1007/s12325-022-02114-4.

References

Lowe F, Batista J, Berges R, Chartier-Kastler E, Conti G, Desgrandchamps F . Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion. Prostate Cancer Prostatic Dis. 2005; 8(3):206-9. DOI: 10.1038/sj.pcan.4500806. View

Hernandez Fernandez C, Ristol Pont J, Estivill E, Batista Miranda J, Lopez Aramburu M . [Importance of nocturia and its impact on quality of sleep and quality of life in patient with benign prostatic hyperplasia]. Actas Urol Esp. 2007; 31(3):262-9. DOI: 10.1016/s0210-4806(07)73632-x. View

Tengs T, Wallace A . One thousand health-related quality-of-life estimates. Med Care. 2000; 38(6):583-637. DOI: 10.1097/00005650-200006000-00004. View

Berges R, Pientka L . Management of the BPH syndrome in Germany: who is treated and how?. Eur Urol. 1999; 36 Suppl 3:21-7. DOI: 10.1159/000052345. View

Chen F, Dai Y, Liu C, Yu H, Liu C, Chen T . Perception of nocturia and medical consulting behavior among community-dwelling women. Int Urogynecol J Pelvic Floor Dysfunct. 2006; 18(4):431-6. DOI: 10.1007/s00192-006-0167-x. View

Speakman M, Batista J, Berges R, Chartier-Kastler E, Conti G, Desgrandchamps F . Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise. Prostate Cancer Prostatic Dis. 2005; 8(4):369-74. DOI: 10.1038/sj.pcan.4500827. View

Van Kerrebroeck P, Abrams P, Chaikin D, Donovan J, Fonda D, Jackson S . The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21(2):179-83. DOI: 10.1002/nau.10053. View

Tikkinen K, Johnson 2nd T, Tammela T, Sintonen H, Haukka J, Huhtala H . Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol. 2009; 57(3):488-96. DOI: 10.1016/j.eururo.2009.03.080. View

Ware Jr J, Kosinski M, Keller S . A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34(3):220-33. DOI: 10.1097/00005650-199603000-00003. View

10.

Berges R, Pientka L, Hofner K, Senge T, Jonas U . Male lower urinary tract symptoms and related health care seeking in Germany. Eur Urol. 2001; 39(6):682-7. DOI: 10.1159/000052527. View

11.

Rodrigues P, Meller A, Campagnari J, Alcantara D, DImperio M . International Prostate Symptom Score--IPSS-AUA as discriminat scale in 400 male patients with lower urinary tract symptoms (LUTS). Int Braz J Urol. 2005; 30(2):135-41. DOI: 10.1590/s1677-55382004000200011. View

12.

Berges R . [Epidemiology of benign prostatic syndrome. Associated risks and management data in German men over age 50]. Urologe A. 2008; 47(2):141-8. DOI: 10.1007/s00120-008-1624-6. View

13.

Berges R, Dreikorn K, Hofner K, Madersbacher S, Michel M, Muschter R . [Diagnostic and differential diagnosis of benign prostate syndrome (BPS): guidelines of the German Urologists]. Urologe A. 2009; 48(11):1356-60, 1362-4. DOI: 10.1007/s00120-009-2066-5. View

14.

Barry M, Fowler Jr F, OLeary M, Bruskewitz R, HOLTGREWE H, MEBUST W . Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med Care. 1995; 33(4 Suppl):AS145-55. View

15.

Norgaard J . The role of nocturia in the quality of life of men with lower urinary tract symptoms. BJU Int. 2010; 105(7):1016-7. DOI: 10.1111/j.1464-410X.2010.09301_1.x. View

16.

Berges R, Oelke M . Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or older. World J Urol. 2011; 29(2):171-8. DOI: 10.1007/s00345-010-0638-z. View

17.

Hutchison A, Farmer R, Verhamme K, Berges R, Navarrete R . The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol. 2006; 51(1):207-15. DOI: 10.1016/j.eururo.2006.06.012. View

18.

Homma Y, Yamaguchi T, Kondo Y, Horie S, Takahashi S, Kitamura T . Significance of nocturia in the International Prostate Symptom Score for benign prostatic hyperplasia. J Urol. 2001; 167(1):172-6. View

19.

Bosch J, Weiss J . The prevalence and causes of nocturia. J Urol. 2012; 189(1 Suppl):S86-92. DOI: 10.1016/j.juro.2012.11.033. View

20.

Clark J, Inui T, Silliman R, Bokhour B, Krasnow S, Robinson R . Patients' perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol. 2003; 21(20):3777-84. DOI: 10.1200/JCO.2003.02.115. View